

## Op2Lysis announces that it has been selected for blended funding (grant and capital) by the European Innovation Council (EIC) accelerator of the Horizon Europe funding program

The European Innovation Council is Europe's flagship innovation program to identify, develop and scale up breakthrough technologies and game changing innovations. The *EIC accelerator* funding opportunity is a very selective program, with success rate of only 5%, intended to support the financing of small and medium-sized enterprises (SMEs) to accelerate innovation programs with high potential for exploitation, in order to bring to market groundbreaking innovations within a 3 to 5 years' time period. Thanks to its adaptative funding scheme including both grant and equity, the ambition of the EIC accelerator program is to play a catalytic role in attracting private investors to companies with high potential. In its first "PILOT" phase, EIC participated in the emergence of 91 centaurs and 2 unicorns in Europe.

The selection of Op2Lysis among the candidates of the October session (cut-off 6) comes at a key stage in the development program of O2L-001, its therapy tailored for hemorrhagic stroke patients. Indeed, Op2Lysis validated its regulatory development plan in September 2021 at the opportunity of a pre-IND consultation with the *Food and Drug Administration* (FDA) and obtained in October 2021 from the FDA the orphan drug designation for its thrombolytic agent. in the treatment of intracerebral hemorrhage. The financial support of the EIC is an additional and important traction to reach the essential milestone of entry into the clinical phase and address this unmet medical need.

*"We are very proud of this achievement for Op2Lysis. Being a winner of the last EIC Accelerator cut-off is a recognition of the progress that have been done these last months by the team and of the good knowledge of our ecosystem. The funding of the EIC Accelerator will be a great support to our progress in the treatment of hemorrhagic stroke patients, as well as to our deep-tech platform to address other life-threatening vascular conditions."* – Jérôme Parcq, CSO Op2Lysis.

*"The recognition by the EIC Accelerator program and the funding in the form of EIC grants and co-investments will allow us to accelerate our development, the industrialization of O2L-001 and our NANOp2Lysis<sup>TM</sup> technology platform to bring us closer to the clinical phase. The funds obtained from the EIC are a very positive signal, a traction to attract new investors in view of a Series A within this year."* – Christophe Gaudin, CEO Op2Lysis

### For further information, please contact

Christophe Gaudin, CEO



[christophe.gaudin@op2lysis.com](mailto:christophe.gaudin@op2lysis.com)



[www.op2lysis.com](http://www.op2lysis.com)



+33 (0) 607 979 008

Jérôme Parcq, CSO



[jerome.parcq@op2lysis.com](mailto:jerome.parcq@op2lysis.com)

<https://www.linkedin.com/company/op2lysis>

**About Op2Lysis – [www.op2lysis.com](http://www.op2lysis.com)**

Op2Lysis is a preclinical stage biotech company developing products using a disruptive technology to ensure best delivery of thrombolytic agents and address acute life-threatening vascular diseases. With its first drug product, O2L-001, Op2Lysis is dedicated to the development of the first medical treatment of hemorrhagic stroke, the most disabling form of stroke. Op2Lysis aspires to become a Leader in developing new treatments for patients suffering from vascular unmet medical needs or life-threatening conditions.

The company is located both in France, with its headquarter in Boulogne-Billancourt, near Paris, and its Research site in Caen, in Normandy, and in Belgium with its affiliate Op2Lysis Development SA near Liège in Wallonia, which is in charge of Development activities.

**Op2Lysis SAS :** 117 Avenue Victor Hugo, 92100 Boulogne-Billancourt, France  
GIP Cyceron, Boulevard Henri Becquerel, 14000 Caen, France

**Op2Lysis Development SA :** Avenue du Parc Industriel 89, 4041 Herstal, Belgium

**About O2L-001**

O2L-001 is a locally administered treatment designed to liquefy the intracerebral hematoma that has formed following a hemorrhagic stroke, so that the blood can be easily removed by a minimally invasive surgical technique and thus reduce the blood volume of the hematoma. The MisTIE clinical trials, performed with a commercially available thrombolytic agent, demonstrate the safety of the procedure and provide a clinical proof of concept for our technology, with a strong association between blood volume reduction and clinical benefit resulting in fewer deaths and disabilities in a sub-population that responded well to treatment. The competitive advantages of O2L-001 observed in the best translational models indicate a much higher potential efficacy and increased safety for this therapeutic indication.

**About EIC Accelerator**

The EIC Accelerator supports individual Small and Medium Enterprises (SMEs), in particular Startups and spinout companies to develop and scaleup game-changing innovations. In some cases small mid-caps (up to 500 employees) are supported.

The EIC Accelerator provides substantial financial support with:

- grant funding (non-dilutive) of up to €2.5 million for innovation development costs,
- investments (direct equity investments) of up to €15 million managed by the EIC Fund for scale-up and other relevant costs.

In addition, EIC selected companies receive coaching, mentoring, access to investors and corporates, and many other opportunities as part of the EIC community.

The EIC welcomes applications from innovators in all EU Member States and countries associated to the Horizon Europe program.